Biotechnology major Biocon on Saturday announced that its 'breakthrough drug', Itolizumab has received Drugs Controller General of India's (DCGI) approval for its use in moderate to......
Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around 8,000 per vial. The company......
'This government did not have any plan for safety stocks of essential medicines.' IMAGE: Doctors attend to a patient suffering from COVID-19 inside the emergency room at the Safdarjung Hospital in......
'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.' Photograph: PTI Photo The market share that Biocon......
The CBI has arrested Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4 lakh bribe to waive the phase three clinical trial of the Insulin Aspart injection, a product of Biocon......
'If people have to build new facilities, and by the time they are operational, it will be time for a new President in the US.' Photograph: Amit Dave/Reuters After registering a net profit of Rs......
Raising overseas debt has become prohibitively expensive due to the depreciating rupee. Photograph: Kind courtesy Jatinder Jeetu/Pixabay Indian companies' foreign borrowings plunged 20.2 per cent......